Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFRaME-O1: Luveltamab Tazevibulin vs Investigator’s Choice in Platinum-resistant Ovarian Cancer
2024-512477-27-00Phase 2Completed
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 2, randomised, open-label trial of luveltamab tazevibulin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Sutro Biopharma, Inc. Primary endpoints: Progression-free survival (PFS) per RECIST v1.1 and Objective response rate (ORR) per RECIST v1.1. Started Jul 2024; status: completed.
02
Drugs
luveltamab tazevibulin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-512477-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512477-27-00.